Table 3 Outcome for phenotypic marker: metastases
From: The clinical use of biomarkers as prognostic factors in Ewing sarcoma
Author | Year | Pt number | P |
|---|---|---|---|
Terrier et al, Eur J Cancer 31 (3), 307-14[36] | 1995 | 315 | 0.003 |
Terrier et al, Semin Diagn Pathol 13 (3), 250-7[37] | 1996 | 315 | S |
Aparicio et al, Oncology 55, 20-6[9] | 1998 | 116 | 0.03 |
De Alava et al, J Clin Oncol 16 (4), 1248-55[38] | 1998 | 99 | 0.008 |
Paulussen et al, J Clin oncol 16 99), 3044-52[39] | 1998 | 114 | S |
Ahmad et al, Cancer 85, 725-31[23] | 1999 | 24 | 0.219 |
Baldini et al, Ann Surg 230 (1), 79-86[40] | 1999 | 37 | 0.002 |
Ginsberg et al, J Clin Oncol 17, 1809-14[11] | 1999 | 85 | 0.33 |
Luksch et al, Tumori 85 (2), 101-7[41] | 1999 | 73 | S |
Cotterill et al, J Clin Oncol 18, 3108-14[24] | 2000 | 975 | 0.0001 |
De Alava et al, Cancer 89, 783-92[25] | 2000 | 55 | 0.02 |
Wei et al, Cancer 89, 793-9[42] | 2000 | 39 | 0.001 |
Jenkin et al, Med Pediatr Oncol 37, 383-9[14] | 2001 | 93 | 0.04 |
Zielenska et al, Cancer 91, 2156-64[43] | 2001 | 26 | 0.0137 |
Martin et al, Arch Surg 138, 281-5[44] | 2003 | 59 | 0.02 |
Fuchs et al, Clin Cancer Res 10, 1344-53[45] | 2004 | 31 | 0.022 |
Matsunobu et al, Clin Cancer Res 10, 1003-12[29] | 2004 | 21 | NS |
Weston et al, B J Cancer 91, 225-32[46] | 2004 | 385 | 0.001 |
Aksnes et al, Acta Oncol 45, 38-46[30] | 2006 | 56 | 0.001 |
Kreuter, Eur J Cancer 45, 1904-11[47] | 2006 | 40 | S |
La et al, Int J Radiat Oncol Biol Phys 64 (2), 544-50[48] | 2006 | 60 | 0.036 |
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] | 2007 | 28 | 0.04 |
Leavey et al, Pediatr blood Cancer 51 (3), 334-8[18] | 2008 | 262 | 0.02 |
Yonemori et al, J Cancer Res Clin Oncol 134, 389-95[34] | 2008 | 79 | 0.02 |
Jawad et al, Cancer 115, 3526-36[19] | 2009 | 385 | 0.001 |
Sari et al, Pediatr Blood Cancer 54, 19-24[21] | 2010 | 87 | 0.001 |
Xie et al, Chin J Cancer 29 (4), 420-4 | 2010 | 18 | 0.01 |